Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aclaris Therapeutics ( (ACRS) ) has shared an update.
On April 28, 2026, Aclaris Therapeutics reported positive full top-line results from a first-in-human Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in healthy volunteers, highlighting a potentially best-in-class pharmacokinetic profile that could support dosing as infrequently as every three months. The company also announced it has chosen lichen planus as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138, underscoring its strategy to address significant Th2- and immune-mediated disease markets where existing biologics generate multibillion-dollar revenues but still leave substantial unmet need.
The most recent analyst rating on (ACRS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
The score is held back mainly by weak financial performance: sharply declining revenue, very large losses, and persistent negative free cash flow. Technicals are relatively supportive with the stock trading above key moving averages, while valuation is constrained by negative earnings and no dividend. Corporate events add a modest positive from improved funding access and early clinical progress, tempered by dilution.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for inflammatory and immunologic diseases, particularly those driven by Type 2 helper T-cell (Th2) pathways. Its pipeline includes biologic and small-molecule candidates aimed at atopic, immunologic, respiratory, and autoimmune conditions, with an emphasis on large, heterogeneous markets such as asthma, atopic dermatitis, and related Th2-driven disorders.
Average Trading Volume: 1,793,713
Technical Sentiment Signal: Hold
Current Market Cap: $518.6M
For detailed information about ACRS stock, go to TipRanks’ Stock Analysis page.